Icahn School of Medicine, Boehringer Ingelheim Collaborate on First Study to Evaluate Nintedanib in Patients With Fibrosing ILD Following COVID-19 Infection
November 20, 2020
November 20, 2020
NEW YORK, Nov. 20 -- The Icahn School of Medicine at Mount Sinai issued the following news release on Nov. 19:
The Icahn School of Medicine at Mount Sinai, Department of Medicine's Clinical Trials Office in collaboration with Boehringer Ingelheim today announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.
"A significant percentage of COVID-19 . . .
The Icahn School of Medicine at Mount Sinai, Department of Medicine's Clinical Trials Office in collaboration with Boehringer Ingelheim today announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.
"A significant percentage of COVID-19 . . .